Dr Reddy's launches novel cancer therapy Toripalimab in India
immuno-oncology drug Toripalimab in India.
Toripalimab is approved by various regulatory authorities around the world including USFDA, European Medicines Agency (EMA), Medicines and Healthcare products Regulatory Agency (MHRA), and others for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC).
Nasopharyngeal carcinoma is a rare, aggressive form of head and neck cancer that originates in the upper part of the throat.
The standard of care for RM-NPC in India before Toripalimab was chemotherapy using drugs such as gemcitabine and cisplatin. Toripalimab is indicated as first-line treatment of adults with metastatic or recurrent locally advanced NPC in combination with gemcitabine and cisplatin.
This combination has shown a 48% reduction in risk of progression or death. Additionally, Toripalimab has also been approved as monotherapy for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after platinum-containing chemotherapy.
Web Development
Django & PostgreSQL Mastery: Build Professional Web Applications
By — Metla Sudha Sekhar, IT Specialist and Developer
Artificial Intelligence(AI)
Mastering C++ Fundamentals with Generative AI: A Hands-On
By — Metla Sudha Sekhar, IT Specialist and Developer
Marketing
Future of Marketing & Branding Masterclass
By — Dr. David Aaker, Professor Emeritus at the Haas School of Business, UC Berkeley, Author | Speaker | Thought Leader | Branding Consultant
Marketing
Digital marketing — Wordpress Website
